Tonix Pharmaceuticals (TNXP) shares gained on Monday after the firm announced a crucial update to its fibromyalgia treatment, Tonmya, which expands coverage to roughly 52 million people in the U.S.
Tonix Pharmaceuticals (TNXP) stock and MapLight Therapeutics (MPLT) stock gains as Raymond James issues them new Strong Buy ratings. Read more here.
Hosted on MSN
TNXP: ~2500 patients have initiated treatment with Tonmya following November 2025 commercial launch
Following the approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) initiated the commercial ...
Tonix remains rated Hold as Tonmya's commercial launch underwhelms, with Q1 2026 net product revenue at $3.7m. Read more on ...
) has been revised to $55.42 / share. This is a decrease of 15.76% from the prior estimate of $65.79 dated April 12, 2026. The price target is an average of many targets provided by analysts. The ...
Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.
BERKELEY HEIGHTS, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial-stage biotechnology company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results